UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
UroGen Pharma (Nasdaq: URGN) will report third quarter 2025 financial results on Thursday, November 6, 2025 prior to market open. A live audio webcast and conference call will follow at 10:00 AM Eastern Time. Investors can access the live webcast and a replay on UroGen’s Investor Relations website; the replay will be available for approximately 30 days. The announcement covers the timing and access details for the Q3 2025 earnings release and related investor call.
UroGen Pharma (Nasdaq: URGN) farà registrare i risultati finanziari del terzo trimestre 2025 giovedì 6 novembre 2025 prima dell'apertura del mercato. Seguirà una trasmissione audio in diretta e una conference call alle 10:00 AM Eastern Time. Gli investitori possono accedere alla trasmissione in diretta e a una replica sul sito di Relazioni con gli Investitori di UroGen; la replica sarà disponibile per circa 30 giorni. L'annuncio descrive i tempi e i dettagli di accesso per la release sugli utili del Q3 2025 e la relativa chiamata agli investitori.
UroGen Pharma (Nasdaq: URGN) anunciará los resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025, antes de la apertura del mercado. Una transmisión de audio en vivo y una conferencia telefónica seguirán a las 10:00 a.m. hora del Este. Los inversores pueden acceder a la transmisión en vivo y a una repetición en el sitio de Relaciones con Inversionistas de UroGen; la repetición estará disponible por aproximadamente 30 días. El anuncio cubre el calendario y los detalles de acceso para el comunicado de resultados del Q3 2025 y la llamada para inversores relacionada.
UroGen Pharma (Nasdaq: URGN)는 2025년 3분기 재무실적을 2025년 11월 6일 목요일 장 전 거래개시 전에 발표합니다. 이어서 라이브 오디오 웹캐스트와 컨퍼런스 콜이 동부 표준시 오전 10:00에 진행됩니다. 투자자들은 UroGen의 IR 웹사이트에서 라이브 웹캐스트와 재생을 이용할 수 있으며, 재생은 대략 30일간 제공됩니다. 발표는 Q3 2025 수익 발표 및 관련 투자자 콜의 시기와 접근 정보를 다룹니다.
UroGen Pharma (Nasdaq : URGN) publiera les résultats financiers du troisième trimestre 2025 le jeudi 6 novembre 2025, avant l’ouverture du marché. Une diffusion audio en direct et une conférence téléphonique suivront à 10 h, heure de l’Est. Les investisseurs pourront accéder à la diffusion en direct et à une réécoute sur le site des Relations investisseurs d’UroGen; la réécoute sera disponible pendant environ 30 jours. L’annonce couvre le calendrier et les détails d’accès pour le communiqué sur les résultats du T3 2025 et l’appel aux investisseurs associé.
UroGen Pharma (Nasdaq: URGN) wird die Finanzergebnisse des dritten Quartals 2025 am Donnerstag, dem 6. November 2025, vor der Börsenöffnung melden. Darauf folgt ein Live-Audio-Webcast und eine Konferenzschaltung um 10:00 Uhr Eastern Time. Investoren können den Live-Webcast und eine Wiedergabe auf der Investor-Relations-Website von UroGen abrufen; die Wiedergabe steht ca. 30 Tage zur Verfügung. Die Ankündigung deckt das Timing und den Zugriff auf die Q3-2025-Erträge und den dazugehörigen Investorenanruf ab.
UroGen Pharma (Nasdaq: URGN) ستعلن عن النتائج المالية للربع الثالث من عام 2025 يوم الخميس 6 نوفمبر 2025 قبل فتح السوق. ستتبع ذلك بث صوتي مباشر ومكالمة مؤتمريه في الساعة 10:00 صباحًا بتوقيت الساحل الشرقي. يمكن للمستثمرين الوصول إلى البث المباشر والإعادة على موقع علاقات المستثمرين الخاص بـ UroGen؛ وستكون الإعادة متاحة لمدة حوالي 30 يومًا. يغطي الإعلان التوقيت وتفاصيل الوصول لإصدار أرباح الربع الثالث من 2025 وللمكالمة الاستثمارية المرتبطة.
- None.
- None.
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
FAQ
When will UroGen (URGN) report third quarter 2025 results?
What time is the UroGen (URGN) Q3 2025 conference call and webcast?
How can investors access the UroGen (URGN) earnings webcast on November 6, 2025?
Will there be a replay of the UroGen (URGN) Q3 2025 earnings call?
Is the UroGen (URGN) Q3 2025 call before or after market open?
